DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $98.00.

Several analysts recently weighed in on the company. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Piper Sandler reiterated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Large investors have recently made changes to their positions in the stock. Capital Insight Partners LLC raised its stake in DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the last quarter. Clear Creek Financial Management LLC increased its holdings in shares of DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after purchasing an additional 120 shares during the period. SeaCrest Wealth Management LLC raised its stake in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after purchasing an additional 152 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its holdings in shares of DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after purchasing an additional 162 shares during the period. Finally, Apollon Wealth Management LLC lifted its holdings in shares of DexCom by 0.7% during the second quarter. Apollon Wealth Management LLC now owns 22,143 shares of the medical device company’s stock worth $2,511,000 after purchasing an additional 163 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DXCM stock opened at $80.04 on Friday. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a fifty day simple moving average of $74.53 and a two-hundred day simple moving average of $83.10. The stock has a market capitalization of $31.26 billion, a price-to-earnings ratio of 47.93, a P/E/G ratio of 2.46 and a beta of 1.12.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.